Literature DB >> 26950735

Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.

Christopher H Crane1, Eugene J Koay1.   

Abstract

The emergence and success of stereotactic body radiation therapy (SBRT) for the treatment of lung cancer have led to its rapid adoption for liver cancers. SBRT can achieve excellent results for small liver tumors. However, the vast majority of physicians interpret SBRT as meaning doses of radiation (range, 4-20 Gray [Gy]) that may not be ablative but are delivered within about 1 week (ie, in 3-6 fractions). Adherence to this approach has limited the effectiveness of SBRT for large liver tumors (>7 cm) because of the need to reduce doses to meet organ constraints. The prognosis for patients who present with large liver tumors is poor, with a median survival ≤12 months, and most of these patients die from tumor-related liver failure. Herein, the authors present a comprehensive solution to achieve ablative SBRT doses for patients with large liver tumors by using a combination of classic, modern, and novel concepts of radiotherapy: fractionation, dose painting, motion management, image guidance, and simultaneous integrated protection. The authors discuss these concepts in the context of large, inoperable liver tumors and review how this approach can substantially prolong survival for patients, most of whom otherwise have a very poor prognosis and few effective treatment options. Cancer 2016;122:1974-86.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  gating; hepatoma; image-guided radiation therapy (IGRT); intrahepatic cholangiocarcinoma; stereotactic ablative radiation therapy

Mesh:

Year:  2016        PMID: 26950735      PMCID: PMC4911237          DOI: 10.1002/cncr.29878

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  62 in total

Review 1.  Partial volume tolerance of the liver to radiation.

Authors:  Laura A Dawson; Randall K Ten Haken
Journal:  Semin Radiat Oncol       Date:  2005-10       Impact factor: 5.934

2.  Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Jatinder Saini; Tobias R Chapman; Robert S Miyaoka; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  Radiother Oncol       Date:  2015-04-28       Impact factor: 6.280

3.  Radiation-induced liver disease.

Authors:  Radwan F Khozouz; Syed Z Huq; Michael C Perry
Journal:  J Clin Oncol       Date:  2008-09-08       Impact factor: 44.544

4.  Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Jeffrey S Morris; Manal M Hassan; Adnan M Siddiqui; E Lin; Lianchun Xiao; Eddie K Abdalla; Jean-Nicolas Vauthey; Thomas A Aloia; Sunil Krishnan; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

5.  Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma.

Authors:  Prajnan Das; Mirna T Abboud; Waqar Haque; Milind Javle; Ahmed Kaseb; Steven A Curley; Jean-Nicolas Vauthey; Thomas A Aloia; A Sam Beddar; Marc E Delclos; Sunil Krishnan; Christopher H Crane
Journal:  Pract Radiat Oncol       Date:  2012-12-08

6.  Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis.

Authors:  Marsha L Haley; Peter C Gerszten; Dwight E Heron; Yue-Fang Chang; Dave S Atteberry; Steven A Burton
Journal:  J Neurosurg Spine       Date:  2011-02-11

7.  The use of 3-D dose volume analysis to predict radiation hepatitis.

Authors:  T S Lawrence; R K Ten Haken; M L Kessler; J M Robertson; J T Lyman; M L Lavigne; M B Brown; D J DuRoss; J C Andrews; W D Ensminger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

8.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

9.  Respiratory gating with EPID-based verification: the MDACC experience.

Authors:  Tina Marie Briere; Sam Beddar; Peter Balter; Ravi Murthy; Sanjay Gupta; Christopher Nelson; George Starkschall; Michael T Gillin; Sunil Krishnan
Journal:  Phys Med Biol       Date:  2009-05-13       Impact factor: 3.609

10.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

View more
  33 in total

Review 1.  Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?

Authors:  Eugene J Koay; Bruno C Odisio; Milind Javle; Jean-Nicolas Vauthey; Christopher H Crane
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 2.  Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Santiago Avila; Danyal A Smani; Eugene J Koay
Journal:  Chin Clin Oncol       Date:  2019-12-19

Review 3.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

4.  Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.

Authors:  Suguru Yamashita; Eugene Jon Koay; Guillaume Passot; Rachna Shroff; Kanwal P Raghav; Claudius Conrad; Yun Shin Chun; Thomas A Aloia; Randa Tao; Ahmed Kaseb; Milind Javle; Christopher H Crane; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2016-12-16       Impact factor: 6.860

Review 5.  SBRT for HCC: Overview of technique and treatment response assessment.

Authors:  Kimberly L Shampain; Caitlin E Hackett; Sohrab Towfighi; Anum Aslam; William R Masch; Alison C Harris; Silvia D Chang; Kanika Khanna; Vivek Mendiratta; Ahmed M Gabr; Dawn Owen; Mishal Mendiratta-Lala
Journal:  Abdom Radiol (NY)       Date:  2021-05-07

6.  Evaluation of respiratory motion-corrected cone-beam CT at end expiration in abdominal radiotherapy sites: a prospective study.

Authors:  Russell E Kincaid; Agung E Hertanto; Yu-Chi Hu; Abraham J Wu; Karyn A Goodman; Hai D Pham; Ellen D Yorke; Qinghui Zhang; Qing Chen; Gig S Mageras
Journal:  Acta Oncol       Date:  2018-01-19       Impact factor: 4.089

Review 7.  The role of imaging in the clinical practice of radiation oncology for pancreatic cancer.

Authors:  Eugene J Koay; William Hall; Peter C Park; Beth Erickson; Joseph M Herman
Journal:  Abdom Radiol (NY)       Date:  2018-02

8.  Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach : A prospective observational study.

Authors:  Rosario Mazzola; Ruggero Ruggieri; Vanessa Figlia; Michele Rigo; Niccolò Giaj Levra; Francesco Ricchetti; Luca Nicosia; Stefanie Corradini; Filippo Alongi
Journal:  Strahlenther Onkol       Date:  2019-01-28       Impact factor: 3.621

9.  Initial Experience of Intentional Internal High-Dose Policy Volumetric Modulated Arc Therapy of Neck Lymph Node Metastases ≥ 2 cm in Patients With Head and Neck Squamous Cell Carcinoma.

Authors:  Tairo Kashihara; Satoshi Nakamura; Naoya Murakami; Kimiteru Ito; Yoshifumi Matsumoto; Kenya Kobayashi; Go Omura; Taisuke Mori; Yoshitaka Honma; Yuko Kubo; Hiroyuki Okamoto; Kana Takahashi; Koji Inaba; Kae Okuma; Hiroshi Igaki; Yuko Nakayama; Ken Kato; Fumihiko Matsumoto; Seiichi Yoshimoto; Jun Itami
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

10.  Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis.

Authors:  Andrew R Kolarich; Jehan L Shah; Thomas J George; Steven J Hughes; Christiana M Shaw; Brian S Geller; Joseph R Grajo
Journal:  J Gastrointest Oncol       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.